Convergent Evolution: Self-Assembly of Small Molecule, Polymeric, and Inorganic Contrast Agents toward Advanced MRI.

Magnetic resonance imaging (MRI) is a non-invasive technique providing detailed anatomical, physiological, and molecular information. Contrast agents (CAs), such as gadolinium-based chelates, enhance differentiation between normal and abnormal tissues, highlight blood vessels, and detect tumors, inflammation, or other conditions, to aid clinical diagnostics. Although small-molecule chelate-based CAs have been used clinically for several years, extensive research efforts have been directed toward enhancing CA properties, ranging from boosting their contrast-to-noise ratio to developing responsive agents, through careful design. This perspective examines the convergent (not chronological) evolution of different classes of CAs: small-molecule complexes, polymeric chelates, and inorganic nanoparticles. We outline how research across these types of CAs has led to self-assembled species showcasing superior MRI performance compared to traditional agents. Despite different mechanisms driving the two main MRI CA classes (positive, T1 and negative, T2), similar strategies have been exploited to drive changes in structure, active-species interaction, and modulation of water access. Self-assembled CAs not only demonstrate considerably slower tumbling rates and enhanced water interactions, which mechanistically boost signal, but also generally manifest improved biodistribution, effective passive targeting to tumor sites, and tuneable clearance pathways when utilized as delivery carriers. These agents further exhibit promise for switchable and active in vivo behavior, valuable in clinical diagnostics. However, despite significant advances, translation to clinic remains a bottleneck due to the complex relationship between mechanistic parameters which define MRI and how they ultimately behave in the body. As such, much work remains, and this perspective aims to inspire by demonstrating how the "old generation" of CAs could evolve to address these challenges.